Buttock Placement of the Implantable Pulse Generator: A New Implantation Technique for Sacral Neuromodulation – A Multicenter StudyScheepens W.A.a · Weil E.H.J.a · van Koeveringe G.A.a · Rohrmann D.b · Hedlund H.E.M.c · Schurch B.d · Ostardo E.e · Pastorello M.f · Ratto C.g · Nordling J.h · van Kerrebroeck P.E.V.a
aDepartment of Urology, University Hospital, Maastricht, The Netherlands; bDepartment of Urology, RWTH, Aachen, Germany; cDepartment of Urology, The National Hospital, Oslo, Norway; dSwiss Paraplegic Centre ‘Paracare’, Zürich, Switzerland; eDepartment of Urology, Ospedale S. Maria degli Angeli, Porderone, Italy; fDepartment of Urology, Negrar Hospital, Verona, Italy; gDepartment of Surgery, Catholic University Largo A. Gemelli, Rome, Italy, and hDepartment of Urology, Herlev Hospital, Copenhagen, Denmark
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Objective: In the standard operation procedure for sacral neuromodulation, the implantable pulse generator (IPG) is implanted in a subcutaneous pocket at the lower part of the anterior abdominal wall. This procedure requires a long operation time and three incisions. With the IPG in the abdominal wall, some patients complain of displacement or pain at the IPG site postoperatively. By modifying the technique of placement of the IPG, these disadvantages are overcome. Methods: Between August 1999 and July 2000, 39 patients underwent a buttock implant of the IPG. In 2 of these patients the position of the IPG was changed from abdominal region to the buttock. During follow–up, complications concerning the operation and location of the IPG were compared to the published literature. Results: Operation time is reduced in all patients by approximately 1 h. No repositioning of the patient is required during surgery. Only a short subcutaneous tunnel is required to connect the lead to the IPG. Pain at the level of the IPG was noted in 10% of the patients, which needed no further treatment. No infections were seen and the IPG did not displace postoperatively. Conclusion: Buttock placement of the IPG in sacral nerve stimulation leads to shorter operation time; only two incisions are needed instead of three and a shorter subcutaneous tunnel is needed. Using this technique there are less complications and a lower re–operation rate.
Van Kerrebroeck PEV: A treatment algorithm for the overactive bladder. Br J Urol 1999;83: (suppl 2):29–30.
Schmidt RA: Applications of neurostimulation in urology. Neurourol Urodyn 1988;7:585– 592.
- Schmidt RA, Senn E, Tanagho EA: Functional evaluation of sacral root integrity: Report of a technique. Urology 1990;35:388–392.
Thon WF, Baskin LS, Jonas U, Tanagho EA, Schmidt RA: Neuromodulation of voiding dysfunction and pelvic pain. World J Urol 1991;9:138–141.
- Dijkema HE, Weil EHJ, Mijs PT, Janknegt RA: Neuromodulation of sacral nerves for incontinence and voiding dysfunctions. Clinical results and complications. Eur Urol 1993;24: 72–76.
- Shaker HS, Hassouna M: Sacral nerve root neuromodulation: An effective treatment for refractory urge incontinence. J Urol 1998;159: 1516–1519.
- Elabaddy AA, Hassouna MM, Elhilali MM: Neural stimulation for chronic voiding dysfunctions. J Urol 1994;152:2076–2080.
- Bosch JL, Groen J: Sacral (S3) segmental nerve stimulation as a treatment for urge incontinence in patients with detrusor instability: Results of chronic electrical stimulation using an implantable neuro prosthesis. J Urol 1995; 154:504–507.
- Shaker HS, Hassouna M: Sacral root neuromodulation in idiopathic non–obstructive chronic urinary retention. J Urol 1998;159: 1476–1478.
Vapnek J, Schmidt RA: Restoration of voiding in chronic urinary retention using the neuroprosthesis. World J Urol 1991;9:142–144.
De Ridder D, Van Cleynenbreugel B, Baert L: Sacral nerve stimulation for female urinary retention: A two–year follow–up. Eur Urol 1999; 35:17.
- Swinn M, Goodwin R, Fowler C: Sacral neuromodulation for young women in urinary retention. Eur Urol 1999;35:17.
- Siegel SW: Management of voiding dysfunction with an implantable neuroprosthesis. Urol Clin North Am 1992;19:163–170.
Thon WF, Baskin LS, Jonas U, Tanagho EA, Schmidt RA: Surgical principles of sacral foramen electrode implantation. World J Urol 1991;9:133–137.
Das A, Siegel S, Schmidt R, and the Sacral Nerve Stimulation Study Group: Abdominal versus upper buttock placement of sacral nerve stimulator. 29th Annual Meeting of ICS Denver, Colo., August 22–26, 1999.
- Weil EHJ, Ruiz Cerda JL, Eerdmans PH, Janknegt RA, Van Kerrebroeck PEV: Clinical results of sacral neuromodulation for chronic voiding dysfunction using unilateral sacral foramen electrodes. World J Urol 1998;16: 313–321.
- Weil EHJ, Ruiz Cerda JL, Eerdmans PH, Janknegt RA, Bemelmans BL, Van Kerrebroeck PEV: Sacral root neuromodulation in the treatment of refractory urge incontinence: A prospective randomized clinical trial. Eur Urol 2000;37:161–171.
- Schmidt PA, Jonas U, Oleson KA, Janknegt RA, Hassouna MM, Siegel SW, Van Kerrebroeck PEV: Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral Nerve Stimulation Study Group. J Urol 1999;162:352–357.
- Hassouna MM, Siegel SW, Lycklama á, Nijeholt AAB, Elhilali MME, Van Kerrebroeck PEV, Das AK, Gajewski JB, Janknegt RA, Rivas DA, Dijkema H, Milam DF, Oleson KA, Schmidt RA: Sacral neuromodulation in the treatment of urgency–frequency symptoms: A multicenter study on efficacy and safety. J Urol 2000;163:1849–1854.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.